Goldman Sachs said that while it expected a transaction with HCR ManorCare due to HCP, Inc.'s
HCP significant debt investment, “we believed the timing of any deal would be closer to the associated debt's maturity in 2012/13.”
That being said, Goldman Sachs writes, “the potential reinvestment of HCP's $1.7 billion investment (about 14% of assets) at an attractive yield and both the size and complexity of the transaction highlight HCP's ability to source attractive growth opportunities.”
Goldman Sachs' questions include:
(1) Real estate values today vs. 2007, the peak of the cycle
(2) Does HCP plan to invest in the operating company or even take a larger position?
(3) How much growth in EBITDA does HCP expect over time?
HCP currently trades at $33.78.
Loading...
Loading...
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in